Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
After finishing at $30.96 in the prior trading day, Stoke Therapeutics Inc (NASDAQ: STOK) closed at $31.05, up 0.29%. In other words, the price has increased by $0.29 from its previous closing price. On the day, 0.66 million shares were traded. STOK stock price reached its highest trading level at $31.54 during the session, while it also had its lowest trading level at $30.1.
Ratios:
Our goal is to gain a better understanding of STOK by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 7.14 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 33.86. For the most recent quarter (mrq), Quick Ratio is recorded 6.53 and its Current Ratio is at 6.53. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In the most recent recommendation for this company, Jefferies on July 18, 2025, initiated with a Buy rating and assigned the stock a target price of $30.
On December 20, 2024, Chardan Capital Markets started tracking the stock assigning a Buy rating and target price of $24.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 03 ’25 when Ticho Barry sold 2,014 shares for $30.65 per share. The transaction valued at 61,725 led to the insider holds 15,156 shares of the business.
Ticho Barry sold 2,006 shares of STOK for $59,743 on Dec 02 ’25. The CHIEF MEDICAL OFFICER now owns 17,170 shares after completing the transaction at $29.78 per share. On Dec 03 ’25, another insider, Kaye Edward M. MD, who serves as the Director of the company, sold 1,070 shares for $30.65 each. As a result, the insider received 32,793 and left with 51,305 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, STOK now has a Market Capitalization of 1773487488 and an Enterprise Value of 1529959552. As of this moment, Stoke’s Price-to-Earnings (P/E) ratio for their current fiscal year is 47.05. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.62 while its Price-to-Book (P/B) ratio in mrq is 5.55. Its current Enterprise Value per Revenue stands at 7.44 whereas that against EBITDA is 52.599.
Stock Price History:
The Beta on a monthly basis for STOK is 1.11, which has changed by 1.3330822 over the last 52 weeks, in comparison to a change of 0.12469888 over the same period for the S&P500. Over the past 52 weeks, STOK has reached a high of $38.69, while it has fallen to a 52-week low of $5.35. The 50-Day Moving Average of the stock is 8.05%, while the 200-Day Moving Average is calculated to be 90.92%.
Shares Statistics:
The stock has traded on average 1.18M shares per day over the past 3-months and 850870 shares per day over the last 10 days, according to various share statistics. A total of 55.12M shares are outstanding, with a floating share count of 45.87M. Insiders hold about 19.69% of the company’s shares, while institutions hold 104.10% stake in the company. Shares short for STOK as of 1763078400 were 11246166 with a Short Ratio of 9.52, compared to 1760486400 on 10831308. Therefore, it implies a Short% of Shares Outstanding of 11246166 and a Short% of Float of 23.599999999999998.
Earnings Estimates
The performance of Stoke Therapeutics Inc (STOK) in the stock market is under the watchful eye of 8.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is -$0.77, with high estimates of -$0.69 and low estimates of -$0.83.
Analysts are recommending an EPS of between $0.26 and -$0.32 for the fiscal current year, implying an average EPS of $0.05. EPS for the following year is -$3.08, with 8.0 analysts recommending between -$2.3 and -$3.65.
Revenue Estimates
9 analysts predict $5.09M in revenue for. The current quarter. It ranges from a high estimate of $7M to a low estimate of $3M. As of. The current estimate, Stoke Therapeutics Inc’s year-ago sales were $22.61M
A total of 9 analysts have provided revenue estimates for STOK’s current fiscal year. The highest revenue estimate was $199.7M, while the lowest revenue estimate was $186.02M, resulting in an average revenue estimate of $189.25M. In the same quarter a year ago, actual revenue was $36.55M
